Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

SVP & GENERAL COUNSEL

SVP AND CFO

EXECUTIVE VP & CSO

SVP OF CORP AFFAIRS & ADMIN.

SVP, CHIEF MEDICAL OFFICER

PRESIDENT & CEO

SR. VP & CCO

SVP and CFO

SVP of Regulatory Affairs

Sr. VP &CPDO

SVP of Corp Affairs & Admin.

SVP, Chief Medical Officer

SVP & General Counsel

President & CEO

Sr. VP & CCO

Executive VP & CSO

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the tr...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-02-13	Premium	acquired	Premium	Premium	Premium	SVP & GENERAL COUNSEL
2024-01-02	Premium	acquired	Premium	Premium	Premium	SVP AND CFO
2022-12-07	Premium	acquired	Premium	Premium	Premium	EXECUTIVE VP & CSO
2022-12-07	Premium	sold	Premium	Premium	Premium	EXECUTIVE VP & CSO
2022-08-18	Premium	sold	Premium	Premium	Premium	SVP OF CORP AFFAIRS & ADMIN.
2022-08-18	Premium	acquired	Premium	Premium	Premium	SVP OF CORP AFFAIRS & ADMIN.
2022-08-17	Premium	acquired	Premium	Premium	Premium	SVP OF CORP AFFAIRS & ADMIN.
2022-08-17	Premium	sold	Premium	Premium	Premium	SVP OF CORP AFFAIRS & ADMIN.
2022-08-17	Premium	acquired	Premium	Premium	Premium	SVP, CHIEF MEDICAL OFFICER
2022-08-17	Premium	sold	Premium	Premium	Premium	SVP, CHIEF MEDICAL OFFICER
2022-08-15	Premium	sold	Premium	Premium	Premium	PRESIDENT & CEO
2022-08-15	Premium	acquired	Premium	Premium	Premium	PRESIDENT & CEO
2022-08-15	Premium	sold	Premium	Premium	Premium	SR. VP & CCO
2022-08-15	Premium	acquired	Premium	Premium	Premium	SR. VP & CCO
2022-08-12	Premium	acquired	Premium	Premium	Premium	SVP AND CFO
2022-08-12	Premium	sold	Premium	Premium	Premium	SVP AND CFO
2022-08-11	Premium	acquired	Premium	Premium	Premium	SVP AND CFO
2022-08-11	Premium	sold	Premium	Premium	Premium	SVP AND CFO
2021-12-23	Premium	sold	Premium	Premium	Premium	SVP and CFO
2021-12-23	Premium	acquired	Premium	Premium	Premium	SVP and CFO
2021-12-08	Premium	acquired	Premium	Premium	Premium	SVP of Regulatory Affairs
2021-12-08	Premium	sold	Premium	Premium	Premium	SVP of Regulatory Affairs
2021-12-08	Premium	acquired	Premium	Premium	Premium	Sr. VP &CPDO
2021-12-08	Premium	sold	Premium	Premium	Premium	Sr. VP &CPDO
2021-12-08	Premium	sold	Premium	Premium	Premium	SVP of Corp Affairs & Admin.

CLDX - Celldex Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for CLDX